NCT07519980 Xanthigen and Its Impact on Weight and Metabolic Health

Eligibility & Interventions

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 180 participants in total. It began in 2026-02-02 with a primary completion date of 2026-07-20.

Brief Summary

Randomized, controlled, triple-blind clinical trial with three parallel arms based on the product consumed (low-dose experimental product, high-dose experimental product, and placebo product) and conducted at a single center to measure the efficacy of a product (Xanthigen®) on overweight or obesity during 16 weeks of consumption.

Eligibility Criteria

Inclusion Criteria: * The subject is able and willing to follow the study protocol procedures to sign the informed consent form prior to the evaluations. * Participants must be between 20 and 50 years of age at the time of consent. * The subject is in good physical and mental health as determined by medical history, physical examination, electrocardiogram, vital signs, biochemistry, and hematology results. * Participants must have a BMI between 27 and 29.9 kg/cm2. * Desire to lose weight. Exclusion Criteria: * Relevant medical history or presence of any medical condition that could interfere with this study, such as a previous diagnosis of diabetes, hypertension, hyperlipidemia, cardiovascular disease, thyroid disease, asthma, arthritis, or inflammatory conditions. * Fasting blood sugar levels greater than 125 mg/dL and/or total cholesterol levels greater than or equal to 240 mg/dL. * Blood pressure levels below 90/140 mm Hg (diastolic/systolic). * Chronic intake of medications/dietary supplements with an impact on body weight or body composition or lipid-modifying products (e.g., protein shakes, statins, omega-3 fatty acids, etc.) 2 months prior to selection or during the study. * Known allergy/sensitivity to any of the components of the investigational product. * Change in hormonal contraception or any use of hormone replacement therapy (HRT) during or at least 3 months prior to the study (if female). * Women of childbearing age who are pregnant or intend to become pregnant during the study period. * Use of any dietary supplements (except mineral supplements, e.g., Ca, Mg). * Participation in any weight loss intervention or recent change in body weight \> 4.5 kg during the last 9 months. * History and/or presence of eating disorders such as bulimia, anorexia nervosa, or binge eating, as determined by the investigator. * Consumption of any dietary supplements (except mineral supplements, e.g., Ca, Mg). * Participation in any weight loss program or recent change in body weight \> 4.5 kg during the last 9 months. * History and/or presence of eating disorders such as bulimia, anorexia nervosa, binge eating, as determined by the investigator. * Individuals who currently participate in aerobic exercise more than 4 times per week, or more than 2.5 hours per week. * Vegan lifestyle. * Current smoker or user of nicotine products or cessation of smoking within 1 year of the screening date. * Gastrointestinal diseases/conditions (colitis ulcers, Crohn's disease, peptic ulcers, celiac disease).

Contact & Investigator

Frequently Asked Questions

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.